Biosimilar Market
Biosimilar Market Study by Recombinant Glycosylated Proteins and Non-Glycosylated Proteins for Hematology, Growth Hormone Deficiency, Oncology, Diabetes, and Autoimmune Diseases from 2024 to 2034
Analysis of Biosimilar Market Covering 30+ Countries Including Analysis of US, Canada, UK, Germany, France, Nordics, GCC countries, Japan, Korea and many more
Biosimilar Market Outlook (2024 to 2034)
Worldwide revenue from the biosimilar market is estimated at US$ 43.8 billion in 2024 and has been analyzed to increase at a CAGR of 8.9% to reach US$ 102.68 billion by 2034.
Biosimilars, also known as follow-on biologics, are created by a different business yet are almost exact replicas of the original medicine. Several acute and chronic illnesses and disorders are treated with biosimilars. Biosimilars are utilized to capture the electrical activity that the human brain produces.
Particularly in low- and middle-income countries where cost is a significant barrier to treatment, the use of biosimilars in cancer treatment has the potential to expand patients' access to potentially life-saving medicines. Additionally, biosimilars might lessen the financial strain on healthcare systems so that more people can get the necessary medical care. Because they provide more accessible and cheaper alternatives for these essential medicines, biosimilars have grown in importance in the treatment of cancer.
Biosimilars and biologics are transforming healthcare through novel therapeutic approaches, improved patient outcomes, and increased accessibility. Consequently, there is a notable increase in demand for them globally.
Biosimilar biologics and biosimilar biologic medications are gaining popularity owing to their increased efficacy and cost.
Because biologics provide focused medicines that explicitly target disease pathways, they have transformed the way that many illnesses are treated. Biologics and biosimilars, in contrast to conventional small-molecule medications, which frequently cause side effects that are not intended, are made to precisely target pathways, reducing unwanted responses.
Generic biologics that are no longer covered by patents are known as biosimilars. The market for biosimilars is anticipated to be propelled by well-known biologics' patent expiry. Sales of biologics have significantly decreased due to the increasing approval and sales of biosimilars. This is contributing to the expansion of the biosimilar market size.
Globally, the prevalence of chronic illnesses has been increasing. The aging population and shifting lifestyles of individuals can be partly blamed for the rise in the incidence of chronic illnesses. Among the prevalent chronic illnesses are diabetes, hypertension, stroke, cancer, obesity, arthritis, and disorders of the mouth and respiratory system. Conversely, rheumatoid arthritis and cancer are being widely treated with biosimilar monoclonal antibodies, leading to biosimilar market growth.
| Report Attribute | Detail |
|---|---|
| Biosimilar Market Size (2024E) | US$ 43.8 Billion |
| Forecasted Market Value (2034F) | US$ 102.68 Billion |
| Global Market Growth Rate (2024 to 2034) | 8.9% CAGR |
| Canada Market Growth Rate (2024 to 2034) | 8.6% CAGR |
| China Market Value (2034F) | US$ 12.41 Billion |
| North America Market Share (2024E) | 38.9% |
| East Asia Market Share (2034F) | 20.4% |
| Key Companies Profiled | Amgen; PFIZER Inc.; Novartis; Biocon Ltd.; Coherus BioScience; Teva Pharmaceuticals; Abbvie; Viatris; Fresenius Kabi; Sanofi SA; Mylan; Amneal Pharmaceuticals, Inc. |
Don't Need a Global Report?
save 40%! on Country & Region specific reports
What are the Projections for the Biosimilar Business Going Forward?
“R&D Investments in Medical Technologies Leading to Innovative Healthcare Solutions”
One of the primary drivers of market expansion is the rising prevalence of acute and chronic illnesses worldwide, driven by various internal and external factors. The growing incidence of Hodgkin's lymphoma, chronic lymphocytic leukemia, granulomatosis with polyangiitis, and microscopic polyangiitis, along with an increasing patient population, especially in emerging nations, is fostering the biosimilar market growth.
Increased investment in R&D capabilities, particularly in both established and emerging nations, focusing on medical equipment and technologies, will further provide lucrative market expansion opportunities. Advances in research and development have led to improvements in healthcare facilities' quality and medical technology. The range of screening exams for research capabilities has also significantly broadened.
Enhanced federal government support is expected to accelerate market growth. Additionally, the expansion of the healthcare sector, driven by both public and private entities, particularly in emerging nations, will create profitable growth opportunities for the personal health devices market.
Market growth is being further supported by the increased adoption of bioidentical hormone replacement therapy by government healthcare institutions. Demand for biological medications has risen due to the aging population and the growing prevalence of chronic illnesses. Biosimilars can help meet this demand and improve patient access to these essential medications.
“Increased Awareness and Understanding of Biosimilars among Public”
Growing public awareness of biosimilars is leading to increased adoption. Biosimilars are widely used in preventing and treating various chronic illnesses, including renal failure, rheumatoid arthritis, diabetes, cancer, autoimmune disorders, cardiovascular diseases, growth hormone deficiency, and infectious diseases. The market for biosimilars is expected to gain momentum in the coming years due to rising healthcare concerns.
Preference for biosimilars over conventional biologics is becoming increasingly prevalent in global markets. This trend is driven by the cost-effectiveness of biosimilars compared to the original biologic medications. Additionally, the growing aging population is expected to drive the demand for biosimilars in the coming years.
Many governmental and commercial organizations are launching campaigns to promote the use of biosimilars instead of traditional biologics and synthetic pharmaceutical products. These efforts are expected to support biosimilar producers' revenue generation potential during the forecast period.
The rapid expansion of the pharmaceutical industry, combined with the rising cost of existing biological pharmaceuticals, should provide favorable growth prospects for the biosimilar market.
What is Hampering Market Expansion to Some Extent?
“High Production Cost and Complex Production Process”
Relatively higher production costs of biosimilars continue to hinder their widespread manufacturing. Additionally, the complexity of the production process is expected to limit the biosimilar market growth drivers.
Sales of biosimilars are likely to be constrained by the availability of affordable generic medications. One clear barrier for market participants is the need to establish biosimilarity through comprehensive analytical characterization. Each biosimilar must be reviewed by relevant regulatory agencies to ensure similarity in terms of safety and efficacy before obtaining regulatory approval. Moreover, subsequent price reductions and competitive pricing in the industry are likely to pose challenges for the marketing of biosimilars.
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
Country-wise Evaluation
The market in South Korea is projected to expand at a CAGR of 9.6% between 2024 and 2034. The country is projected to account for 19.4% of the East Asia biosimilar market share by the end of 2034.
What is Benefitting Biosimilar Manufacturers in the United States?
“Adoption of Biosimilars Contributing to Reduced Direct Spending on Biologics”
| Attribute | United States |
|---|---|
| Market Value (2024E) | US$ 14.44 Billion |
| Growth Rate (2024 to 2034) | 9% CAGR |
| Projected Value (2034F) | US$ 34.27 Billion |
Clinical and financial benefits of biosimilars are proving to be quite promising for the United States’ healthcare system.
- By the end of 2026, the RAND Corporation estimates that widespread global adoption of these medications could reduce direct spending on biologics by US$ 54 billion.
Various drug manufacturers are engaging in strategic partnerships, collaborations, and acquisitions for research, production, or commercialization to gain a competitive edge, which is one of the key biosimilar market trends in the United States. These partnerships aim to provide patients in a range of therapeutic areas with access to high-quality, reasonably priced medications.
- For example, to strengthen its position through its pipeline of future biosimilar drugs and its portfolio, Biocon Biologics entered into a definitive agreement in February 2022 to purchase the biosimilars business of Viatris, a global franchise specializing in oncology, immunology, and endocrinology.
Why are More Businesses Heading to China?
“Enhanced Production Efficiencies Enabling Better Patient Access to Essential Treatments”
| Attribute | China |
|---|---|
| Market Value (2024E) | US$ 4.73 Billion |
| Growth Rate (2024 to 2034) | 10.1% CAGR |
| Projected Value (2034F) | US$ 12.41 Billion |
Development and production of biosimilars and biologics have advanced significantly in China's pharmaceutical industry, offering substantial potential for expansion, innovation, and improved patient access to life-saving treatments. Advances in biotechnology and manufacturing techniques have enabled the nation to produce biologics and biosimilars more effectively and economically.
Category-wise Evaluation
Based on application, the growth hormone deficiency segment is expected to reach a valuation of US$ 1.84 billion in 2024.
What Makes Recombinant Glycosylated Proteins Stand Out in the Market?
“Effectiveness in Treating Wide Range of Illnesses”
| Attribute | Recombinant Glycosylated Proteins |
|---|---|
| Segment Value (2024E) | US$ 33.26 Billion |
| Growth Rate (2024 to 2034) | 8.8% CAGR |
| Projected Value (2034F) | US$ 77.39 Billion |
Significant portion of the biosimilar market is occupied by recombinant glycosylated proteins, which are quickly becoming a well-known product class. These proteins are gaining recognition in the industry due to their advanced therapeutic potential and ability to treat a wide range of illnesses. Their increasing popularity signifies a promising development in the variety of products offered by the biosimilar sector.
How is Use of Biosimilars Making Cancer Therapies More Accessible?
“Biosimilars Seen as Cost-Effective Alternative to Expensive Biologics”
| Attribute | Oncology |
|---|---|
| Segment Value (2024E) | US$ 20.41 Billion |
| Growth Rate (2024 to 2034) | 9.6% CAGR |
| Projected Value (2034F) | US$ 50.91 Billion |
Use of biosimilars is significantly advancing cancer treatment by making therapies more widely available and affordable. Biosimilars hold great promise for increasing patient access to life-saving medications, especially in low- and middle-income countries where the cost of care is a major obstacle. The growing use of biosimilars in cancer therapy is truly revolutionary.
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
Market Landscape
Key players in the biosimilar industry are actively adapting themselves to the evolving market trends such as the application of fusion biosimilars and oncology biosimilars.
- In January 2024, Gilead Sciences and Arcus Biosciences announced an updated partnership agreement and a separate equity investment. Gilead invested US$ 320 billion in Arcus common shares at US$ 21 per share.
- In May 2023, Biocon Biologics and Viatris Inc. announced the introduction of Abevmy in Canada. This medication is a bevacizumab biosimilar of Avastin, originally developed by Roche, and has been approved by Health Canada for use in cancer treatment.
- In March 2022, Amneal Pharmaceuticals, Inc. declared that the U.S. government had accepted the Biologics License Application (BLA) for filgrastim-ayow, a biosimilar referencing Neupogen.
- In May 2022, the United States Food and Drug Administration (FDA) approved Amneal Pharmaceuticals, Inc.'s Biologics License Application (BLA) for pegfilgrastim-pbbk, a biosimilar referencing Neulasta.
Fact.MR provides detailed information about the price points of key biosimilar manufacturers positioned across the world, sales growth, production capacity, and speculative technological expansion in this new biosimilar market report.
Key Segments of Biosimilar Market Research
-
By Product Type :
- Recombinant Glycosylated Proteins
- Recombinant Non-Glycosylated Proteins
-
By Application :
- Hematology
- Growth Hormone Deficiency
- Oncology
- Diabetes
- Autoimmune Disease
- Others
-
By Distribution Channel :
- Hospital Pharmacies
- Online Pharmacies
- Retail Pharmacies
-
By Region :
- North America
- Latin America
- Eastern Europe
- Western Europe
- East Asia
- South Asia & Pacific
- Middle East & Africa
Table of Content
- 1. Executive Summary
- 2. Industry Introduction, including Taxonomy and Market Definition
- 3. Market Trends and Success Factors, including Macro-economic Factors, Market Dynamics, and Recent Industry Developments
- 4. Global Market Demand Analysis 2019 to 2023 and Forecast 2024 to 2034, including Historical Analysis and Future Projections
- 5. Pricing Analysis
- 6. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034
- 6.1. Application
- 6.2. Product Type
- 6.3. Distribution Channel
- 7. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, by Application
- 7.1. Hematology
- 7.2. Growth Hormone Deficiency
- 7.3. Oncology
- 7.4. Diabetes
- 7.5. Autoimmune Disease
- 7.6. Others
- 8. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, by Product Type
- 8.1. Recombinant Glycosylated Proteins
- 8.2. Recombinant Non-Glycosylated Proteins
- 9. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, by Distribution Channel
- 9.1. Hospital Pharmacies
- 9.2. Online Pharmacies
- 9.3. Retail Pharmacies
- 10. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, by Region
- 10.1. North America
- 10.2. Latin America
- 10.3. Western Europe
- 10.4. Eastern Europe
- 10.5. East Asia
- 10.6. South Asia & Pacific
- 10.7. Middle East & Africa
- 11. North America Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries
- 12. Latin America Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries
- 13. Western Europe Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries
- 14. Eastern Europe Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries
- 15. East Asia Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries
- 16. South Asia & Pacific Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries
- 17. Middle East & Africa Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries
- 18. Sales Forecast 2024 to 2034 by Application, Product Type, Distribution Channel, and Region for 30 Countries
- 19. Competition Outlook, including Market Structure Analysis, Company Share Analysis by Key Players, and Competition Dashboard
- 20. Company Profile
- 20.1. Amgen
- 20.2. PFIZER Inc.
- 20.3. Novartis
- 20.4. Biocon Ltd.
- 20.5. Coherus BioScience
- 20.6. Teva Pharmaceuticals
- 20.7. Abbvie
- 20.8. Viatris
- 20.9. Fresenius Kabi
- 20.10. Sanofi SA
- 20.11. Mylan
- 20.12. Amneal Pharmaceuticals, Inc.
- 21. Assumptions and Acronyms Applied
- 22. Research Methodology
Don't Need a Global Report?
save 40%! on Country & Region specific reports
List Of Table
Table 01: Global Market Value (US$ Mn) Analysis, by Application, 2019 to 2023
Table 02: Global Market Value (US$ Mn) Analysis, by Application, 2024 to 2034
Table 03: Global Market Value (US$ Mn) Opportunity Analysis, by Application, 2024 to 2034
Table 04: Global Market Value (US$ Mn) Analysis, by Product Type, 2019 to 2023
Table 05: Global Market Value (US$ Mn) Analysis, by Product Type, 2024 to 2034
Table 06: Global Market Value (US$ Mn) Opportunity Analysis, by Product Type, 2024 to 2034
Table 07: Global Market Value (US$ Mn) Analysis, by Distribution Channel, 2019 to 2023
Table 08: Global Market Value (US$ Mn) Analysis, by Distribution Channel, 2024 to 2034
Table 09: Global Market Value (US$ Mn) Opportunity Analysis, by Distribution Channel, 2024 to 2034
Table 10: Global Market Value (US$ Mn) Analysis, by Region, 2019 to 2023
Table 11: Global Market Value (US$ Mn) Analysis, by Region, 2024 to 2034
Table 12: Global Market Value (US$ Mn) Opportunity Analysis, by Region, 2024 to 2034
Table 13: North America Market Value (US$ Mn) Analysis, by Country, 2019 to 2023
Table 14: North America Market Value (US$ Mn) Analysis, by Country, 2024 to 2034
Table 15: North America Market Value (US$ Mn) Opportunity Analysis, by Country, 2024 to 2034
Table 16: North America Market Value (US$ Mn) Analysis, by Application, 2019 to 2023
Table 17: North America Market Value (US$ Mn) Analysis, by Application, 2024 to 2034
Table 18: North America Market Value (US$ Mn) Opportunity Analysis, by Application, 2024 to 2034
Table 19: North America Market Value (US$ Mn) Analysis, by Product Type, 2019 to 2023
Table 20: North America Market Value (US$ Mn) Analysis, by Product Type, 2024 to 2034
Table 21: North America Market Value (US$ Mn) Opportunity Analysis, by Product Type, 2024 to 2034
Table 22: North America Market Value (US$ Mn) Analysis, by Distribution Channel, 2019 to 2023
Table 23: North America Market Value (US$ Mn) Analysis, by Distribution Channel, 2024 to 2034
Table 24: North America Market Value (US$ Mn) Opportunity Analysis, by Distribution Channel, 2024 to 2034
Table 25: Latin America Market Value (US$ Mn) Analysis, by Country, 2019 to 2023
Table 26: Latin America Market Value (US$ Mn) Analysis, by Country, 2024 to 2034
Table 27: Latin America Market Value (US$ Mn) Opportunity Analysis, by Country, 2024 to 2034
Table 28: Latin America Market Value (US$ Mn) Analysis, by Application, 2019 to 2023
Table 29: Latin America Market Value (US$ Mn) Analysis, by Application, 2024 to 2034
Table 30: Latin America Market Value (US$ Mn) Opportunity Analysis, by Application, 2024 to 2034
Table 31: Latin America Market Value (US$ Mn) Analysis, by Product Type, 2019 to 2023
Table 32: Latin America Market Value (US$ Mn) Analysis, by Product Type, 2024 to 2034
Table 33: Latin America Market Value (US$ Mn) Opportunity Analysis, by Product Type, 2024 to 2034
Table 34: Latin America Market Value (US$ Mn) Analysis, by Distribution Channel, 2019 to 2023
Table 35: Latin America Market Value (US$ Mn) Analysis, by Distribution Channel, 2024 to 2034
Table 36: Latin America Market Value (US$ Mn) Opportunity Analysis, by Distribution Channel, 2024 to 2034
Table 37: Western Europe Market Value (US$ Mn) Analysis, by Country, 2019 to 2023
Table 38: Western Europe Market Value (US$ Mn) Analysis, by Country, 2024 to 2034
Table 39: Western Europe Market Value (US$ Mn) Opportunity Analysis, by Country, 2024 to 2034
Table 40: Western Europe Market Value (US$ Mn) Analysis, by Application, 2019 to 2023
Table 41: Western Europe Market Value (US$ Mn) Analysis, by Application, 2024 to 2034
Table 42: Western Europe Market Value (US$ Mn) Opportunity Analysis, by Application, 2024 to 2034
Table 43: Western Europe Market Value (US$ Mn) Analysis, by Product Type, 2019 to 2023
Table 44: Western Europe Market Value (US$ Mn) Analysis, by Product Type, 2024 to 2034
Table 45: Western Europe Market Value (US$ Mn) Opportunity Analysis, by Product Type, 2024 to 2034
Table 46: Western Europe Market Value (US$ Mn) Analysis, by Distribution Channel, 2019 to 2023
Table 47: Western Europe Market Value (US$ Mn) Analysis, by Distribution Channel, 2024 to 2034
Table 48: Western Europe Market Value (US$ Mn) Opportunity Analysis, by Distribution Channel, 2024 to 2034
Table 49: Eastern Europe Market Value (US$ Mn) Analysis, by Country, 2019 to 2023
Table 50: Eastern Europe Market Value (US$ Mn) Analysis, by Country, 2024 to 2034
Table 51: Eastern Europe Market Value (US$ Mn) Opportunity Analysis, by Country, 2024 to 2034
Table 52: Eastern Europe Market Value (US$ Mn) Analysis, by Application, 2019 to 2023
Table 53: Eastern Europe Market Value (US$ Mn) Analysis, by Application, 2024 to 2034
Table 54: Eastern Europe Market Value (US$ Mn) Opportunity Analysis, by Application, 2024 to 2034
Table 55: Eastern Europe Market Value (US$ Mn) Analysis, by Product Type, 2019 to 2023
Table 56: Eastern Europe Market Value (US$ Mn) Analysis, by Product Type, 2024 to 2034
Table 57: Eastern Europe Market Value (US$ Mn) Opportunity Analysis, by Product Type, 2024 to 2034
Table 58: Eastern Europe Market Value (US$ Mn) Analysis, by Distribution Channel, 2019 to 2023
Table 59: Eastern Europe Market Value (US$ Mn) Analysis, by Distribution Channel, 2024 to 2034
Table 60: Eastern Europe Market Value (US$ Mn) Opportunity Analysis, by Distribution Channel, 2024 to 2034
Table 61: East Asia Market Value (US$ Mn) Analysis, by Country, 2019 to 2023
Table 62: East Asia Market Value (US$ Mn) Analysis, by Country, 2024 to 2034
Table 63: East Asia Market Value (US$ Mn) Opportunity Analysis, by Country, 2024 to 2034
Table 64: East Asia Market Value (US$ Mn) Analysis, by Application, 2019 to 2023
Table 65: East Asia Market Value (US$ Mn) Analysis, by Application, 2024 to 2034
Table 66: East Asia Market Value (US$ Mn) Opportunity Analysis, by Application, 2024 to 2034
Table 67: East Asia Market Value (US$ Mn) Analysis, by Product Type, 2019 to 2023
Table 68: East Asia Market Value (US$ Mn) Analysis, by Product Type, 2024 to 2034
Table 69: East Asia Market Value (US$ Mn) Opportunity Analysis, by Product Type, 2024 to 2034
Table 70: East Asia Market Value (US$ Mn) Analysis, by Distribution Channel, 2019 to 2023
Table 71: East Asia Market Value (US$ Mn) Analysis, by Distribution Channel, 2024 to 2034
Table 72: East Asia Market Value (US$ Mn) Opportunity Analysis, by Distribution Channel, 2024 to 2034
Table 73: South Asia & Pacific Market Value (US$ Mn) Analysis, by Country, 2019 to 2023
Table 74: South Asia & Pacific Market Value (US$ Mn) Analysis, by Country, 2024 to 2034
Table 75: South Asia & Pacific Market Value (US$ Mn) Opportunity Analysis, by Country, 2024 to 2034
Table 76: South Asia & Pacific Market Value (US$ Mn) Analysis, by Application, 2019 to 2023
Table 77: South Asia & Pacific Market Value (US$ Mn) Analysis, by Application, 2024 to 2034
Table 78: South Asia & Pacific Market Value (US$ Mn) Opportunity Analysis, by Application, 2024 to 2034
Table 79: South Asia & Pacific Market Value (US$ Mn) Analysis, by Product Type, 2019 to 2023
Table 80: South Asia & Pacific Market Value (US$ Mn) Analysis, by Product Type, 2024 to 2034
Table 81: South Asia & Pacific Market Value (US$ Mn) Opportunity Analysis, by Product Type, 2024 to 2034
Table 82: South Asia & Pacific Market Value (US$ Mn) Analysis, by Distribution Channel, 2019 to 2023
Table 83: South Asia & Pacific Market Value (US$ Mn) Analysis, by Distribution Channel, 2024 to 2034
Table 84: South Asia & Pacific Market Value (US$ Mn) Opportunity Analysis, by Distribution Channel, 2024 to 2034
Table 85: MEA Market Value (US$ Mn) Analysis, by Country, 2019 to 2023
Table 86: MEA Market Value (US$ Mn) Analysis, by Country, 2024 to 2034
Table 87: MEA Market Value (US$ Mn) Opportunity Analysis, by Country, 2024 to 2034
Table 88: MEA Market Value (US$ Mn) Analysis, by Application, 2019 to 2023
Table 89: MEA Market Value (US$ Mn) Analysis, by Application, 2024 to 2034
Table 90: MEA Market Value (US$ Mn) Opportunity Analysis, by Application, 2024 to 2034
Table 91: MEA Market Value (US$ Mn) Analysis, by Product Type, 2019 to 2023
Table 92: MEA Market Value (US$ Mn) Analysis, by Product Type, 2024 to 2034
Table 93: MEA Market Value (US$ Mn) Opportunity Analysis, by Product Type, 2024 to 2034
Table 94: MEA Market Value (US$ Mn) Analysis, by Distribution Channel, 2019 to 2023
Table 95: MEA Market Value (US$ Mn) Analysis, by Distribution Channel, 2024 to 2034
Table 96: MEA Market Value (US$ Mn) Opportunity Analysis, by Distribution Channel, 2024 to 2034
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
List Of Figures
Figure 01: Global Market Value (US$ Mn) Historical Analysis, 2019 to 2023
Figure 02: Global Market Value (US$ Mn) Forecast and Analysis, 2024 to 2034
Figure 03: Global Market Value Y-o-Y Growth and Forecast, 2019 to 2034
Figure 04: Global Market Incremental $ Opportunity, 2024 to 2034
Figure 05: Global Market Share and BPS Analysis by Application, 2024 & 2034
Figure 06: Global Market Y-o-Y Growth Projections by Application, 2024 to 2034
Figure 07: Global Market Attractiveness Analysis by Application, 2024 to 2034
Figure 08: Global Market Share and BPS Analysis by Product Type, 2024 & 2034
Figure 09: Global Market Y-o-Y Growth Projections by Product Type, 2024 to 2034
Figure 10: Global Market Attractiveness Analysis by Product Type, 2024 to 2034
Figure 11: Global Market Share and BPS Analysis by Distribution Channel, 2024 & 2034
Figure 12: Global Market Y-o-Y Growth Projections by Distribution Channel, 2024 to 2034
Figure 13: Global Market Attractiveness Analysis by Distribution Channel, 2024 to 2034
Figure 14: Global Market Share and BPS Analysis by Region, 2024 & 2034
Figure 15: Global Market Y-o-Y Growth Projections by Region, 2024 to 2034
Figure 16: Global Market Attractiveness Analysis by Region, 2024 to 2034
Figure 17: North America Market Value (US$ Mn) Historical Analysis, 2019 to 2023
Figure 18: North America Market Value (US$ Mn) Forecast and Analysis, 2024 to 2034
Figure 19: North America Market Value Y-o-Y Growth and Forecast, 2034
Figure 20: North America Market Incremental $ Opportunity, 2024 to 2034
Figure 21: North America Market Share Analysis by Country, 2024 & 2034
Figure 22: North America Market Y-o-Y Growth Projection by Country, 2024 to 2034
Figure 23: North America Market Attractiveness Analysis by Country, 2024 to 2034
Figure 24: North America Market Share and BPS Analysis by Application, 2024 & 2034
Figure 25: North America Market Y-o-Y Growth Projections by Application, 2024 to 2034
Figure 26: North America Market Attractiveness Analysis by Application, 2024 to 2034
Figure 27: North America Market Share and BPS Analysis by Product Type, 2024 & 2034
Figure 28: North America Market Y-o-Y Growth Projections by Product Type, 2024 to 2034
Figure 29: North America Market Attractiveness Analysis by Product Type, 2024 to 2034
Figure 30: North America Market Share and BPS Analysis by Distribution Channel, 2024 & 2034
Figure 31: North America Market Y-o-Y Growth Projections by Distribution Channel, 2024 to 2034
Figure 32: North America Market Attractiveness Analysis by Distribution Channel, 2024 to 2034
Figure 33: Latin America Market Value (US$ Mn) Historical Analysis, 2019 to 2023
Figure 34: Latin America Market Value (US$ Mn) Forecast and Analysis, 2024 to 2034
Figure 35: Latin America Market Value Y-o-Y Growth and Forecast, 2019 to 2034
Figure 36: Latin America Market Incremental $ Opportunity, 2024 to 2034
Figure 37: Latin America Market Share Analysis by Country, 2024 & 2034
Figure 38: Latin America Market Y-o-Y Growth Projection by Country, 2024 to 2034
Figure 39: Latin America Market Attractiveness Analysis by Country, 2024 to 2034
Figure 40: Latin America Market Share and BPS Analysis by Application, 2024 & 2034
Figure 41: Latin America Market Y-o-Y Growth Projections by Application, 2024 to 2034
Figure 42: Latin America Market Attractiveness Analysis by Application, 2024 to 2034
Figure 43: Latin America Market Share and BPS Analysis by Product Type, 2024 & 2034
Figure 44: Latin America Market Y-o-Y Growth Projections by Product Type, 2024 to 2034
Figure 45: Latin America Market Attractiveness Analysis by Product Type, 2024 to 2034
Figure 46: Latin America Market Share and BPS Analysis by Distribution Channel, 2024 & 2034
Figure 47: Latin America Market Y-o-Y Growth Projections by Distribution Channel, 2024 to 2034
Figure 48: Latin America Market Attractiveness Analysis by Distribution Channel, 2024 to 2034
Figure 49: Western Europe Market Value (US$ Mn) Historical Analysis, 2019 to 2023
Figure 50: Western Europe Market Value (US$ Mn) Forecast and Analysis, 2024 to 2034
Figure 51: Western Europe Market Value Y-o-Y Growth and Forecast, 2019 to 2034
Figure 52: Western Europe Market Incremental $ Opportunity, 2024 to 2034
Figure 53: Western Europe Market Share Analysis by Country, 2024 & 2034
Figure 54: Western Europe Market Y-o-Y Growth Projection by Country, 2024 to 2034
Figure 55: Western Europe Market Attractiveness Analysis by Country, 2024 to 2034
Figure 56: Western Europe Market Share and BPS Analysis by Application, 2024 & 2034
Figure 57: Western Europe Market Y-o-Y Growth Projections by Application, 2024 to 2034
Figure 58: Western Europe Market Attractiveness Analysis by Application, 2024 to 2034
Figure 59: Western Europe Market Share and BPS Analysis by Product Type, 2024 & 2034
Figure 60: Western Europe Market Y-o-Y Growth Projections by Product Type, 2024 to 2034
Figure 61: Western Europe Market Attractiveness Analysis by Product Type, 2024 to 2034
Figure 62: Western Europe Market Share and BPS Analysis by Distribution Channel, 2024 & 2034
Figure 63: Western Europe Market Y-o-Y Growth Projections by Distribution Channel, 2024 to 2034
Figure 64: Western Europe Market Attractiveness Analysis by Distribution Channel, 2024 to 2034
Figure 66: Eastern Europe Market Value (US$ Mn) Historical Analysis, 2019 to 2023
Figure 67: Eastern Europe Market Value (US$ Mn) Forecast and Analysis, 2024 to 2034
Figure 68: Eastern Europe Market Value Y-o-Y Growth and Forecast, 2019 to 2034
Figure 69: Eastern Europe Market Incremental $ Opportunity, 2024 to 2034
Figure 70: Eastern Europe Market Share Analysis by Country, 2024 & 2034
Figure 71: Eastern Europe Market Y-o-Y Growth Projection by Country, 2024 to 2034
Figure 72: Eastern Europe Market Attractiveness Analysis by Country, 2024 to 2034
Figure 73: Eastern Europe Market Share and BPS Analysis by Application, 2024 & 2034
Figure 74: Eastern Europe Market Y-o-Y Growth Projections by Application, 2024 to 2034
Figure 75: Eastern Europe Market Attractiveness Analysis by Application, 2024 to 2034
Figure 76: Eastern Europe Market Share and BPS Analysis by Product Type, 2024 & 2034
Figure 77: Eastern Europe Market Y-o-Y Growth Projections by Product Type, 2024 to 2034
Figure 78: Eastern Europe Market Attractiveness Analysis by Product Type, 2024 to 2034
Figure 79: Eastern Europe Market Share and BPS Analysis by Distribution Channel, 2024 & 2034
Figure 80: Eastern Europe Market Y-o-Y Growth Projections by Distribution Channel, 2024 to 2034
Figure 81: Eastern Europe Market Attractiveness Analysis by Distribution Channel, 2024 to 2034
Figure 82: East Asia Market Value (US$ Mn) Historical Analysis, 2019 to 2023
Figure 83: East Asia Market Value (US$ Mn) Forecast and Analysis, 2024 to 2034
Figure 84: East Asia Market Value Y-o-Y Growth and Forecast, 2019 to 2034
Figure 85: East Asia Market Incremental $ Opportunity, 2024 to 2034
Figure 86: East Asia Market Share Analysis by Country, 2024 & 2034
Figure 87: East Asia Market Y-o-Y Growth Projection by Country, 2024 to 2034
Figure 88: East Asia Market Attractiveness Analysis by Country, 2024 to 2034
Figure 89: East Asia Market Share and BPS Analysis by Application, 2024 & 2034
Figure 90: East Asia Market Y-o-Y Growth Projections by Application, 2024 to 2034
Figure 91: East Asia Market Attractiveness Analysis by Application, 2024 to 2034
Figure 92: East Asia Market Share and BPS Analysis by Product Type, 2024 & 2034
Figure 93: East Asia Market Y-o-Y Growth Projections by Product Type, 2024 to 2034
Figure 94: East Asia Market Attractiveness Analysis by Product Type, 2024 to 2034
Figure 95: East Asia Market Share and BPS Analysis by Distribution Channel, 2024 & 2034
Figure 96: East Asia Market Y-o-Y Growth Projections by Distribution Channel, 2024 to 2034
Figure 97: East Asia Market Attractiveness Analysis by Distribution Channel, 2024 to 2034
Figure 98: South Asia & Pacific Market Value (US$ Mn) Historical Analysis, 2019 to 2023
Figure 99: South Asia & Pacific Market Value (US$ Mn) Forecast and Analysis, 2024 to 2034
Figure 100: South Asia & Pacific Market Value Y-o-Y Growth and Forecast, 2019 to 2034
Figure 101: South Asia & Pacific Market Incremental $ Opportunity, 2024 to 2034
Figure 102: South Asia & Pacific Market Share Analysis by Country, 2024 & 2034
Figure 103: South Asia & Pacific Market Y-o-Y Growth Projection by Country, 2024 to 2034
Figure 104: South Asia & Pacific Market Attractiveness Analysis by Country, 2024 to 2034
Figure 105: South Asia & Pacific Market Share and BPS Analysis by Application, 2024 & 2034
Figure 106: South Asia & Pacific Market Y-o-Y Growth Projections by Application, 2024 to 2034
Figure 107: South Asia & Pacific Market Attractiveness Analysis by Application, 2024 to 2034
Figure 108: South Asia & Pacific Market Share and BPS Analysis by Product Type, 2024 & 2034
Figure 109: South Asia & Pacific Market Y-o-Y Growth Projections by Product Type, 2024 to 2034
Figure 110: South Asia & Pacific Market Attractiveness Analysis by Product Type, 2024 to 2034
Figure 111: South Asia & Pacific Market Share and BPS Analysis by Distribution Channel, 2024 & 2034
Figure 112: South Asia & Pacific Market Y-o-Y Growth Projections by Distribution Channel, 2024 to 2034
Figure 113: South Asia & Pacific Market Attractiveness Analysis by Distribution Channel, 2024 to 2034
Figure 114: MEA Market Value (US$ Mn) Historical Analysis, 2019 to 2023
Figure 115: MEA Market Value (US$ Mn) Forecast and Analysis, 2024 to 2034
Figure 116: MEA Market Value Y-o-Y Growth and Forecast, 2019 to 2034
Figure 117: MEA Market Incremental $ Opportunity, 2024 to 2034
Figure 118: MEA Market Share Analysis by Country, 2024 & 2034
Figure 119: MEA Market Y-o-Y Growth Projection by Country, 2024 to 2034
Figure 120: MEA Market Attractiveness Analysis by Country, 2024 to 2034
Figure 121: MEA Market Share and BPS Analysis by Application, 2024 & 2034
Figure 122: MEA Market Y-o-Y Growth Projections by Application, 2024 to 2034
Figure 123: MEA Market Attractiveness Analysis by Application, 2024 to 2034
Figure 124: MEA Market Share and BPS Analysis by Product Type, 2024 & 2034
Figure 125: MEA Market Y-o-Y Growth Projections by Product Type, 2024 to 2034
Figure 126: MEA Market Attractiveness Analysis by Product Type, 2024 to 2034
Figure 127: MEA Market Share and BPS Analysis by Distribution Channel, 2024 & 2034
Figure 128: MEA Market Y-o-Y Growth Projections by Distribution Channel, 2024 to 2034
Figure 129: MEA Market Attractiveness Analysis by Distribution Channel, 2024 to 2034
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
- FAQs -
What is the size of the biosimilar market in 2024?
The global market for biosimilars is estimated at US$ 43.8 billion in 2024.
What is the market trend for biosimilars?
Demand for biosimilars is forecasted to increase at a CAGR of 8.9% from 2024 to 2034.
What is the sales outlook for biosimilars by 2034?
The biosimilar market is forecasted to reach a value of US$ 102.68 billion by 2034.
What is the projected size of the market in Japan for 2034?
Sales of biosimilars in Japan are projected to reach US$ 4.44 billion by 2034.
Which type of biosimilar is in high demand?
Demand for recombinant glycosylated proteins is projected to reach a market value of US$ 33.26 billion in 2024.
Who are the top manufacturers of biosimilars across the world?
Some of the leading companies in the market are Amgen, PFIZER Inc., Novartis, and Biocon Ltd.
Biosimilar Market